WEST CONSHOHOCKEN, Pa. and OTTAWA--(BUSINESS WIRE)--July 20, 2006--Zelos Therapeutics, Inc., a biopharmaceutical company focused on developing novel, clinical stage therapies for patients at increased risk of bone fractures, today announced the addition of Colin Goddard, Ph.D., to its Board of Directors. Dr. Goddard, who is Chief Executive Officer of OSI Pharmaceuticals, Inc., brings over 20 years of corporate development and operations experience to the Zelos Board.
